ArticleNAR genomics and bioinformatics2025
Fully haplotyped genome assemblies of healthy individuals reveal variability in 5'ss strength and support by splicing regulatory proteins.
Article in NAR genomics and bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This work presents a comprehensive investigation of sequence variations at human 5' splice sites (5'ss), exploring their impact on 5'ss strength and predicted splicing regulatory protein (SRP) binding. Leveraging 44 high-quality genomes, with fully haplotyped assemblies, we were able to fully assess homozygous and heterozygous sequence variations around and within 5'ss. Variations showed differing tolerance levels in protein-coding and non-coding transcripts. Around half of 5'ss variations did not alter 5'ss strength (measured by the HBond score, that estimates binding of the 11 nucleotides at the free U1 spliceosomal RNA 5' end). Heterozygous variations resulted in stronger 5'ss strength reductions and less compensatory effects of multiple sequence variations at the same 5'ss, compared to homozygous variations. Additionally, we observed a slight balance between changes in 5'ss strength and predicted SRP binding. Strong 5'ss (HBond score >18.8) showed strength variations in both directions, as theoretically expected for random distributions, whereas weaker 5'ss consistently showed lower strength reductions than expected or achievable. Variations at 5'ss of essential genes were less frequent than in other genes and showed a higher amount of variations that did not alter 5'ss strength. Acceptable changes in predicted SRP binding sites were highly dependent on their respective 5'ss strength.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.